Laurus Labs plans ₹3,000 cr capex, targets 30% margins
pre-market1 source ↓machine-written, see hownot a recommendation
- LAURUSLABS close
- ₹2,323
- On the day
- -1.06%
- Futures OI, short build-up
- +2.4%
- Put-call ratio
- 0.86
- Max pain
- ₹2,200
Laurus Labs reported a record consolidated revenue of ₹2,206 cr in Q2 FY27, while first-half revenue reached ₹4,233 cr, up 31% year on year. Quarterly EBITDA stood at ₹762 cr, giving a 34.5% margin, an improvement of 2.7 percentage points. The company is investing around ₹3,000 cr to expand manufacturing capacity and is targeting EBITDA margins above 30% as it broadens its CDMO portfolio and enters newer modalities such as peptides and oligonucleotides. Pharma manufacturing 🧪 remains the central growth focus.
Key Points:
• The company’s specialised manufacturing push addresses rising demand for complex drug-development and CDMO capabilities, where technical expertise and regulatory compliance can support higher-value contracts.
• The reported Q2 margin was already above the company’s stated 30% threshold. Sustaining that level while deploying the planned capex will depend on capacity utilisation, product mix and the pace of commercialisation across newer modalities.
• The shares closed at ₹2,320 on 03 Nov 2026, down from ₹2,347 previously, according to Trade Brains. OI Charts data recorded a close of ₹2,323, down 1.06%, with volume of 4,026,149 shares. The stock had gained 8.4% over five sessions and 17.3% over 20 sessions, after trading between ₹917.95 on 02 Feb 2026 and ₹2,442 on 02 Nov 2026.
For derivatives participants, OI Charts data showed futures open interest rising 2.4% to 17,921,400 shares, indicating a short build-up on the session. The futures premium was negative at 0.03%, while the put-call ratio stood at 0.86. In the 23 Nov 2026 expiry, ₹2,400 carried the largest call open interest and ₹2,000 the largest put open interest. Max pain was at ₹2,200, giving traders the key positioning levels to monitor as the recent rally meets fresh short positioning
The next focus is the execution of the ₹3,000 cr investment plan, including capacity additions, customer qualification and progress in peptides and oligonucleotides. Investors will also track whether revenue growth and the 34.5% Q2 EBITDA margin hold as the expansion moves forward. The developments are relevant across pharma and contract manufacturing, where specialised capabilities are becoming increasingly important ⚕️.
Source: Trade Brains, 03 Nov 2026
Not investment advice. For informational purposes only.